|
Platelet compatibility assessment between AML patients and platelet donors by flow cytometry
|
M. Sayyadi   , M. Shaiegan , M. Nikouguftar , M. Vaezi , A. Malek-Mohammadi , M.H. Ahmadi , S. Mohammadi , M. Zadsar |
|
|
| Keywords: Key words: Flow Cytometry, Crossmatching٬ Blood, Platelet-Rich Plasma |
|
|
Full-Text [PDF 300 kb]
(1264 Downloads)
| Abstract (HTML) (6328 Views)
|
Type of Study: Research |
Subject:
Imunohematology
Published: 2016/03/14
|
|
|
|
|
|
|
Full-Text: (3610 Views) |
References :
- Thiagarajan P, Afshar-Kharghan V. Platelet transfusion therapy. Hematol Oncol Clin North Am 2013; 27(3): 629-43.
- Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician 2011; 83(6): 719-24.
- Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70(1): 23-30.
- Freedman J, Gafni A, Garvey M, Blanchette V. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion. 1989; 29(3): 201-7.
- Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, et al. Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity. Transfusion 2000; 40(12): 1446-56.
- Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142(3): 348-60
- Slichter SJ, Bolgiano D, Kao KJ, Kickler TS, McFarland J, McCullough J, et al. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfusion Med Rev 2011; 25(2): 102-10.
- Lee HJ, Yeom JS, Park JS, Park ES, Seo JH, Lim JY, et al. Clinical Significance of Antibodies Against Platelet HLA Class I in Children with Idiopathic Thrombocytopenic Purpura. Korean Journal of Blood Transfusion 2013; 24(3): 233-40
- Kurz M, Knöbl P, Kalhs P, Greinix HT, Höcker P, Panzer S. Platelet-reactive HLA antibodies associated with low post transfusion platelet increments: a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test. Transfusion 2001; 41(6): 771-4.
- Peterson JA, McFarland JG, Curtis BR, Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol 2013; 161(1): 3-14.
- Curtis B, McFarland J. Human platelet antigens–2013. Vox Sang 2014; 106(2): 93-102.
- Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005; 45(3): 366-73.
- Arnold DM, Clare R, Salib M, Clayden R, Wang G, Nazi I, et al. The Mcmaster ITP Registry: Assessing the Prevalence, Clinical and Laboratory Features of Immune Thrombocytopenia. Blood 2014; 124(21): 5008-13.
- Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18(3): 149-65.
- Claas FH. Predictive parameters for in vivo alloreactivity. Transpl Immunol 2002; 10(2): 137-42.
- Döhlinger S, Humpe A, Connor J, Köhler M, Legler TJ. Flow-cytometric screening of platelet antibodies with previously frozen cells. J Immunol Methods 2005;
297(1): 169-75.
- McFarland JG. Detection and identification of platelet antibodies in clinical disorders. Transfus Apher Sci 2003; 28(3): 297-305.
- Gates K, MacPherson BR. Retrospective evaluation of flow cytometry as a platelet crossmatching procedure. Cytometry 1994; 18(3): 123-8.
- Triulzi DJ, Assmann SF, Strauss RG, Ness P, Hess JR, Kaufman RM, et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012; 119(23): 5553-62.
- Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105(10): 4106-14.
- Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000; 14(2): 180-96.
- Sayed D, Bakry R, El-Sharkawy N, Zahran A, Khalaf MR. Flow cytometric platelet cross-matching to predict platelet transfusion in acute leukemia. J Clin Apher 2011; 26(1): 23-8.
- Rioux-Massé B, Cohn C, Lindgren B, Pulkrabek S, McCullough J. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion 2014; 54(12): 3080-7.
|
Sci J Iran Blood Transfus Organ 2016; 13(1): 29-37
|
Platelet compatibility assessment between AML patients
and platelet donors by flow cytometry
Sayyadi M.1, Shaiegan M.1, Nikougoftar Zarif M.1, Vaezi M.2, Malek Mohammadi A.2,
Ahmadi M.H.1, Mohammadi S.2, Zadsar M.1
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran, Iran
Abstract
Background and Objectives
One of the complications of repeated platelet transfusion is immune platelet refractoriness. In this study, a flow cytometic platelet cross-matching was performed to evaluate platelet transfusion outcome.
Materials and Methods
In this descriptive study, fifteen patients with a history of multiple platelet transfusions and fifteen healthy participants as the control group were enrolled in this study. Platelet cross-match was done and analyzed by the gate method. EDTA-anticoagulated blood samples from healthy donors were collected and PRP sampls were obtained. The serum of each patient was added to platelet suspension and incubated with FITC-anti human IgG and was analyzed using a flow cytometer. Platelet cross-match results of the patients were compared with those of CCI.
Results
Platelet cross match results were negatively correlated with 1-hour (r = -0.731, p = 0.002) and 24-hour (r = -0.794, p = 0.001) CCIs. There was a significant difference in the mean percentage of platelet crossmatch between the patients with immune platelet refractoriness (showing 1-hour CCIs less than 7500) and that of the control group and the patients without platelet refractoriness.
Conclusions
The results showed that there was a significant correlation between platelet cross match by flowcytometry and 1-hour CCI results and this method could be applicable in the evaluation of platelet transfusion outcome.
| Key words: Flow Cytometry, Crossmatching٬ Blood, Platelet-Rich Plasma |
|
Received: 4 Aug 2015
Accepted: 26 Dec 2015
Correspondence: Shaiegan M., PhD of Immunology. Associate Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 88601564; Fax: (+9821) 88601599
E-mail:
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Sayyadi M, Shaiegan M, Nikouguftar M, Vaezi M, Malek-Mohammadi A, Ahmadi M, et al . Platelet compatibility assessment between AML patients and platelet donors by flow cytometry. Sci J Iran Blood Transfus Organ 2016; 13 (1) :29-37 URL: http://bloodjournal.ir/article-1-983-en.html
|
.jpg)
.png)
